[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA117800C2 - Похідні урацилу або тиміну для лікування гепатиту с - Google Patents

Похідні урацилу або тиміну для лікування гепатиту с

Info

Publication number
UA117800C2
UA117800C2 UAA201302816A UAA201302816A UA117800C2 UA 117800 C2 UA117800 C2 UA 117800C2 UA A201302816 A UAA201302816 A UA A201302816A UA A201302816 A UAA201302816 A UA A201302816A UA 117800 C2 UA117800 C2 UA 117800C2
Authority
UA
Ukraine
Prior art keywords
compounds
salts
timin
uracyl
hepatitis
Prior art date
Application number
UAA201302816A
Other languages
English (en)
Inventor
Рольф Вагнер
Майкл Д. ТУФАНО
Кент Д. СТЮАРТ
Тодд У. Роквей
Джон Т. Рендольф
Джон К. Претт
Крістофер Е. Моттер
Клеренс Дж. Мейрінг
Кентон Л. Лондженекер
Йайа Ліу
Дейчунь Ліу
Аллен К. Крюгер
Уоррен М. Кейті
Дуглас К. Хатчінсон
Пеггі П. Хуанг
Чарльз А. Флентдж
Памела Л. Доннер
Девід А. Дегуй
Девід А. Бітебеннер
Девід М. Барнес
Шуанг ЧЕН
ІІ Тадіус С. Франчік
Йі Гао
Ентоні Р. Хайт
Джон І. Хенгевельд
Роджер Ф. Генрі
Брайєн Дж. Котекі
Сяочунь ЛОУ
Кеті Сарріс
Джефф Г. З. Жанг
Original Assignee
Еббві Айрленд Анлімітед Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117800(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еббві Айрленд Анлімітед Компані filed Critical Еббві Айрленд Анлімітед Компані
Priority claimed from UAA201004147A external-priority patent/UA104995C2/uk
Publication of UA117800C2 publication Critical patent/UA117800C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Даний винахід належить до: (a) до сполук та їх солей, які, серед інших, інгібують HCV; (b) до проміжних сполук, придатних для одержання таких сполук та солей; (c) до композицій, що містять такі сполуки та солі; (d) до способів одержання таких проміжних сполук, сполук, солей та композицій; (e) до способів застосування таких сполук, солей та композицій; та (f) до наборів, що містять такі сполуки, солі та композиції.
UAA201302816A 2007-09-17 2008-09-17 Похідні урацилу або тиміну для лікування гепатиту с UA117800C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US9679108P 2008-09-13 2008-09-13
UAA201004147A UA104995C2 (uk) 2007-09-17 2008-09-17 Похідні урацилу або тиміну для лікування гепатиту с

Publications (1)

Publication Number Publication Date
UA117800C2 true UA117800C2 (uk) 2018-10-10

Family

ID=39948002

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201302816A UA117800C2 (uk) 2007-09-17 2008-09-17 Похідні урацилу або тиміну для лікування гепатиту с

Country Status (31)

Country Link
US (3) US8415351B2 (uk)
EP (2) EP2725015A1 (uk)
JP (2) JP5734654B2 (uk)
KR (2) KR101552474B1 (uk)
CN (2) CN102746239B (uk)
AR (2) AR070027A1 (uk)
AU (1) AU2008302448B2 (uk)
BR (1) BRPI0816994B8 (uk)
CA (2) CA2699981C (uk)
CL (2) CL2008002794A1 (uk)
CO (1) CO6260076A2 (uk)
CR (2) CR11316A (uk)
DO (2) DOP2010000084A (uk)
ES (1) ES2453591T3 (uk)
GT (1) GT201000061A (uk)
HK (1) HK1147256A1 (uk)
IL (1) IL204547A (uk)
IN (1) IN2012DN05113A (uk)
MX (2) MX2010002905A (uk)
MY (1) MY162760A (uk)
NZ (3) NZ584720A (uk)
PA (1) PA8796201A1 (uk)
PE (2) PE20130209A1 (uk)
PH (1) PH12013500365A1 (uk)
RU (2) RU2543620C2 (uk)
SG (1) SG183733A1 (uk)
TW (2) TWI534137B (uk)
UA (1) UA117800C2 (uk)
UY (1) UY31344A1 (uk)
WO (1) WO2009039127A1 (uk)
ZA (2) ZA201204223B (uk)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548873A1 (en) * 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
RU2014147354A (ru) * 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
EP2725015A1 (en) * 2007-09-17 2014-04-30 AbbVie Bahamas Ltd. Uracil or thymine derivative for treating hepatitis c
EP2222660B1 (en) * 2007-11-16 2014-03-26 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CN102099335A (zh) 2008-07-23 2011-06-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
AU2009295981A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating HCV
NZ594923A (en) * 2009-03-24 2013-11-29 Abbott Lab Process for preparing antiviral compound
US8741914B2 (en) * 2009-03-25 2014-06-03 Abbvie Inc. Antiviral compounds and uses thereof
WO2010111653A2 (en) * 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
JP2012530751A (ja) * 2009-06-24 2012-12-06 エフ．ホフマン−ラ ロシュ アーゲー 複素環式の抗ウイルス性化合物
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
AU2010297290A1 (en) 2009-09-21 2012-03-15 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2501679A1 (en) * 2009-11-21 2012-09-26 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
RU2012129657A (ru) * 2009-12-14 2014-01-27 Ф.Хоффманн-Ля Рош Аг Гетероциклические противовирусные соединения
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
MX2012014235A (es) 2010-07-07 2013-01-28 Hoffmann La Roche Compuestos hetericiclicos antiviricos.
CA2805748A1 (en) * 2010-07-16 2012-01-19 Shashank Shekhar Process for preparing n-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
MX338725B (es) 2010-07-16 2016-04-28 Abbvie Bahamas Ltd Ligando de fosfina para reacciones cataliticas.
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
KR101382730B1 (ko) 2010-08-13 2014-04-08 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
TWI558400B (zh) 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
SG10202010626PA (en) * 2011-03-31 2020-11-27 Schaefer Konstanze Perfluorinated compounds for the non-viral transfer of nucleic acids
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
KR20140062476A (ko) 2011-08-01 2014-05-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 우라실 유도체 및 그 의약 용도
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2861576B1 (en) 2012-05-15 2018-01-10 Novartis AG Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CA2870339C (en) 2012-05-15 2020-06-02 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
ES2670601T3 (es) 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
WO2013171640A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2866807A2 (en) 2012-06-27 2015-05-06 Abbvie Inc. Methods for treating hcv
CA2882624A1 (en) 2012-08-21 2014-02-27 Shashank Shekhar Process for preparing antiviral compounds
CA2888883A1 (en) * 2012-10-18 2014-04-24 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
WO2015004028A1 (de) 2013-07-08 2015-01-15 Bayer Cropscience Ag Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20150209403A1 (en) 2014-01-28 2015-07-30 Abbvie Inc. Dose Adjustment
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
US10517870B2 (en) * 2015-07-30 2019-12-31 Bristol-Myers Squibb Company Aryl substituted bicycle heteroaryl compounds
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
RU2018121946A (ru) 2015-11-20 2019-12-23 Вайтаи Фармасьютиклз, Ллк Модуляторы ror-гамма
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
EP4031247A1 (en) * 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (uk) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
ATE357433T1 (de) 1999-12-06 2007-04-15 Hoffmann La Roche 4-pyrimidinyl-n-acyl-l-phenylanine
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167956A (en) * 2000-02-04 2009-02-11 Sumitomo Chemical Co Isocyanate compounds
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
TW200505872A (en) * 2003-06-13 2005-02-16 Lg Life Science Ltd Hepatitis C virus inhibitors
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
EP2725015A1 (en) * 2007-09-17 2014-04-30 AbbVie Bahamas Ltd. Uracil or thymine derivative for treating hepatitis c
RU2014147354A (ru) * 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
EP2548873A1 (en) 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
CN102099335A (zh) 2008-07-23 2011-06-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物

Also Published As

Publication number Publication date
CL2008002794A1 (es) 2009-09-04
NZ618277A (en) 2015-07-31
CA2699981A1 (en) 2009-03-26
US20120213733A1 (en) 2012-08-23
PE20130209A1 (es) 2013-03-24
AU2008302448B2 (en) 2014-11-06
TWI437994B (zh) 2014-05-21
NZ600371A (en) 2014-07-25
CR20150238A (es) 2015-07-01
AR087472A2 (es) 2014-03-26
TWI534137B (zh) 2016-05-21
UY31344A1 (es) 2009-04-30
CN102746239A (zh) 2012-10-24
PA8796201A1 (es) 2009-04-23
TW201443027A (zh) 2014-11-16
MY162760A (en) 2017-07-14
IL204547A0 (en) 2010-11-30
JP2010539186A (ja) 2010-12-16
NZ584720A (en) 2012-07-27
IN2012DN05113A (uk) 2015-10-23
US20140235638A1 (en) 2014-08-21
PE20090705A1 (es) 2009-07-17
KR20150117632A (ko) 2015-10-20
CN102746239B (zh) 2016-02-10
SG183733A1 (en) 2012-09-27
RU2599635C2 (ru) 2016-10-10
HK1147256A1 (en) 2011-08-05
AR070027A1 (es) 2010-03-10
US8415351B2 (en) 2013-04-09
ZA201204224B (en) 2015-12-23
JP2013049681A (ja) 2013-03-14
CN101801935A (zh) 2010-08-11
CA2976793A1 (en) 2009-03-26
EP2222646A1 (en) 2010-09-01
AU2008302448A1 (en) 2009-03-26
RU2013104270A (ru) 2014-08-10
JP5734654B2 (ja) 2015-06-17
TW200918066A (en) 2009-05-01
PH12013500365A1 (en) 2014-09-08
WO2009039127A1 (en) 2009-03-26
MX338555B (es) 2016-04-20
CL2013000372A1 (es) 2013-10-04
CA2699981C (en) 2017-08-22
MX2010002905A (es) 2010-07-05
GT201000061A (es) 2012-03-26
DOP2010000084A (es) 2010-06-15
US8685991B2 (en) 2014-04-01
BRPI0816994A2 (pt) 2015-03-24
IL204547A (en) 2016-04-21
US9095590B2 (en) 2015-08-04
RU2543620C2 (ru) 2015-03-10
US20110070193A1 (en) 2011-03-24
DOP2010000396A (es) 2013-12-31
BRPI0816994B1 (pt) 2019-12-24
CO6260076A2 (es) 2011-03-22
KR101660360B1 (ko) 2016-09-27
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
ZA201204223B (en) 2015-12-23
CN101801935B (zh) 2014-12-03
EP2222646B1 (en) 2014-01-22
KR101552474B1 (ko) 2015-09-11
KR20100068289A (ko) 2010-06-22
ES2453591T3 (es) 2014-04-08
RU2010114828A (ru) 2011-10-27
BRPI0816994B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
CY1115893T1 (el) Anti-μολυσματικες πυριμιδινες και χρησεις αυτων
HRP20070043A2 (en) Antiviral compounds
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA200971074A1 (ru) Антивирусные соединения
EA201170772A1 (ru) Органические соединения
EA200970156A1 (ru) Пиридизиноновые производные
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
MX2010009646A (es) Agentes terapeuticos antivirales.
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
HRP20070078A2 (en) Nucleoside phosphonate conjugates as anti hiv agents
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
ECSP088518A (es) Nucleósidos antivirales
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA201190293A1 (ru) Пролекарства триптолида
EA201370078A1 (ru) Ингибиторы вируса гепатита с
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments